One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
ILC2s in Virus-induced Asthma Exacerbations: A Starring or Supportive Role?
Marc B. Hershenson
doi : 10.1164/rccm.202108-2001ed
Volume 204, Issue 11, pp: 1239–1240
COVID-19–related Acute Respiratory Distress Syndrome Subphenotypes and Differential Response to Corticosteroids: Time for More Precision?
Kiran Reddy 1, Charles Corey Hardin 2, and Daniel Francis McAuley 1,3
doi : 10.1164/rccm.202109-2213ed
Volume 204, Issue 11, pp: 1241–1243
New Insights into the Comparative Effectiveness of Fentanyl and Morphine Infusions in ICU Patients
Paul J. Young 1,2,3 and Audrey De Jong 4
doi : 10.1164/rccm.202109-2112ed
Volume 204, Issue 11, pp: 1243–1245
Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations
Valerie Waters
doi : 10.1164/rccm.202108-1939ed
Volume 204, Issue 11, pp: 1245–1247
Integrated Biomarkers for Pulmonary Nodules: Proving What Is Possible
Douglas Arenberg
doi : 10.1164/rccm.202108-2002ed
Volume 204, Issue 11, pp: 1247–1248
Using Isoniazid More Safely and More Effectively: The Time Is Now
Neil W. Schluger
doi : 10.1164/rccm.202108-1938ed
Volume 204, Issue 11, pp: 1248–1250
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal
Bartolome R. Celli 1*, Leonardo M. Fabbri 2*‡, Shawn D. Aaron 3, Alvar Agusti 4,5,6,7, Robert Brook 8, Gerard J. Criner 9‡, Frits M. E. Franssen 10,11, Marc Humbert 12,13, John R. Hurst 14, Denis O’Donnell 15, Leonardo Pantoni 16, Show All...
doi : 10.1164/rccm.202108-1819pp
Volume 204, Issue 11, pp: 1251–1258
Pulmonary Innate Lymphoid Cell Responses during Rhinovirus-induced Asthma Exacerbations In Vivo: A Clinical Trial
Jaideep Dhariwal 1,2,3, Aoife Cameron 1,2, Ernie Wong 1,2, Malte Paulsen 4, Maria-Belen Trujillo-Torralbo 1,2, Ajerico del Rosario 1,2, Eteri Bakhsoliani 1,2, Tatiana Kebadze 1,2, Mark Almond 1,2, Hugo Farne 1,2, Leila Gogsadze 1,2, Julia Aniscenko 1,2, Batika M. J. Rana 2,5, Trevor T. Hansel 1,2, David J. Jackson 2,4,5, Onn Min Kon 1,2, Michael R. Edwards 1,2, Roberto Solari 1,2, David J. Cousins 2,5,6, Ross P. Walton 1,2*, and Sebastian L. Johnston 1,2*; on behalf of the MRC-GSK Strategic Alliance Consortium
doi : 10.1164/rccm.202010-3754oc
Volume 204, Issue 11, pp: 1259–1273
Type 2 innate lymphoid cells (ILC2s) are significant sources of type 2 cytokines, which are implicated in the pathogenesis of asthma and asthma exacerbations. The role of ILC2s in virus-induced asthma exacerbations is not well characterized.
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids
Pratik Sinha 1*, David Furfaro 2*, Matthew J. Cummings 2, Darryl Abrams 2, Kevin Delucchi 3, Manoj V. Maddali 4, June He 1, Alison Thompson 2, Michael Murn 2, John Fountain 5, Amanda Rosen 5, Shelief Y. Robbins-Juarez 6, Matthew A. Adan 6, Tejus Satish 6, Mahesh Madhavan 7, Aakriti Gupta 7, Alexander K. Lyashchenko 8, Cara Agerstrand 2, Natalie H. Yip 2, Kristin M. Burkart 2, Jeremy R. Beitler 2, Matthew R. Baldwin 2, Carolyn S. Calfee 9,10,11‡, Daniel Brodie 2‡, and Max R. O’Donnell 2,12‡
doi : 10.1164/rccm.202105-1302oc
Volume 204, Issue 11, pp: 1274–1285
Two distinct subphenotypes have been identified in acute respiratory distress syndrome (ARDS), but the presence of subgroups in ARDS associated with coronavirus disease (COVID-19) is unknown.
A Phase II Cluster-Crossover Randomized Trial of Fentanyl versus Morphine for Analgosedation in Mechanically Ventilated Patients
Andrew J. Casamento 1,2,3, Ary Serpa Neto 1,3,4,5,6, Marcus Young 3,5, Mervin Lawrence 2, Christina Taplin 2, Glenn M. Eastwood 1,3, Angajendra Ghosh 2,7, and Rinaldo Bellomo 1,3,4,5; for the Assessment of Opioid Administration to Lead to Analgesic Effects and Sedation in Intensive Care (ANALGESIC) trial centers
doi : 10.1164/rccm.202106-1515oc
Volume 204, Issue 11, pp: 1286–1294
The continuous infusion of fentanyl or morphine is often prescribed to assist with analgesia and sedation (analgosedation) during mechanical ventilation.
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment
Christopher H. Goss 1,2,3*, Sonya L. Heltshe 2,3*, Natalie E. West 4, Michelle Skalland 3, Don B. Sanders 5, Raksha Jain 6, Tara L. Barto 7, Barbra Fogarty 3, Bruce C. Marshall 8, Donald R. VanDevanter 9, and Patrick A. Flume 10,11; on behalf of the STOP2 Investigators
doi : 10.1164/rccm.202102-0461oc
Volume 204, Issue 11, pp: 1295–1305
People with cystic fibrosis (CF) experience acute worsening of respiratory symptoms and lung function known as pulmonary exacerbations. Treatment with intravenous antimicrobials is common; however, there is scant evidence to support a standard treatment duration.
Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules
Michael N. Kammer 1,2, Dhairya A. Lakhani 1*, Aneri B. Balar 1, Sanja L. Antic 1, Amanda K. Kussrow 2,3,4, Rebekah L. Webster 2, Shayan Mahapatra 1, Udaykamal Barad 5, Chirayu Shah 5, Thomas Atwater 1, Brenda Diergaarde 6, Jun Qian 1, Alexander Kaizer 7, Melissa New 8, Erin Hirsch 7, William J. Feser 7, Jolene Strong 9, Matthew Rioth 10, York E. Miller 8, Yoganand Balagurunathan 11, Dianna J. Rowe 1, Sherif Helmey 1, Sheau-Chiann Chen 12, Joseph Bauza 13, Stephen A. Deppen 1, Kim Sandler 1, Fabien Maldonado 1, Avrum Spira 14, Ehab Billatos 14, Matthew B. Schabath 11, Robert J. Gillies 11, David O. Wilson 15, Ronald C. Walker 5, Bennett Landman 1,16, Heidi Chen 13, Eric L. Grogan 1, Anna E. Barón 7, Darryl J. Bornhop 2,3,4, and Pierre P. Massion 1,4,17†
doi : 10.1164/rccm.202012-4438oc
Volume 204, Issue 11, pp: 1306–1316
Patients with indeterminate pulmonary nodules (IPNs) at risk of cancer undergo high rates of invasive, costly, and morbid procedures.
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment
Renu Verma 1, Sunita Patil 1, Nan Zhang 2, Flora M. F. Moreira 3, Marize T. Vitorio 3, Andrea da S. Santos 3, Ellen Wallace 4, Devasena Gnanashanmugam 4, David H. Persing 4, Rada M. Savic 2, Julio Croda 5,6, and Jason R. Andrews 1
doi : 10.1164/rccm.202103-0564oc
Volume 204, Issue 11, pp: 1317–1326
Standardized dosing of antitubercular drugs contributes to a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug concentrations achieved. SNPs in the NAT2 (N-acetyltransferase-2) gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH). However, an obstacle to implementing pharmacogenomic-guided dosing is the lack of a point-of-care assay.
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial
Kamunkhwala Gausi 1, Elisa H. Ignatius 2, Xin Sun 3, Soyeon Kim 4, Laura Moran 5, Lubbe Wiesner 1, Florian von Groote-Bidlingmaier 6, Richard Hafner 7, Kathleen Donahue 8, Naadira Vanker 6, Susan L. Rosenkranz 3, Susan Swindells 9, Andreas H. Diacon 6, Eric L. Nuermberger 2, Kelly E. Dooley 2, and Paolo Denti 1; on behalf of the A5312 Study Team
doi : 10.1164/rccm.202103-0534oc
Volume 204, Issue 11, pp: 1327–1335
There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate–level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown.
Diagnosis of Pulmonary Hypertension Using Dynamic Chest Radiography
Yuzo Yamasaki 1, Takeshi Kamitani 1, Kohtaro Abe 2, Kazuya Hosokawa 2, Koji Sagiyama 1, Tomoyuki Hida 1, Yuko Matsuura 1, Yoshiyuki Kitamura 1, Yasuhiro Maruoka 1, Takuro Isoda 1, Shingo Baba 1, Hideki Yoshikawa 3, Taku Kuramoto 3, Hidetake Yabuuchi 4, and Kousei Ishigami 1
doi : 10.1164/rccm.202102-0387im
Volume 204, Issue 11, pp: 1336–1337
Postobstructive Pulmonary Edema after Nonlethal Suicidal Hanging
Jerry Shu-Hung Kuo 1, Sheng-Yuan Ruan 1, Chun-Ta Huang 1, and Wei-Ting Chen 2
doi : 10.1164/rccm.202101-0009im
Volume 204, Issue 11, pp: e113–e114
Daily Step Counts Are Associated with Hospitalization Risk in Pulmonary Arterial Hypertension
Jennifer Marvin-Peek 1, Anna Hemnes 1, Shi Huang 1, Luke Silverman-Loyd 2, Grant MacKinnon 3, Jeffrey Annis 1, Seth S. Martin 4, Michael J. Blaha 4, and Evan L. Brittain 1*
doi : 10.1164/rccm.202104-1035le
Volume 204, Issue 11, pp: 1338–1340
Modern Lung Magnetic Resonance Imaging to Screen for Pulmonary Complications in Patients with Dyskeratosis Congenita
Laura L. Walkup 1,2*, Kasiani C. Myers 1,2, Matthew M. Willmering 1, Parinda A. Mehta 1,2, Adam S. Nelson 1,2, Robert J. Fleck 1,2, Jason C. Woods 1,2, Stella M. Davies 1,2, and Christopher T. Towe 1,2
doi : 10.1164/rccm.202103-0736le
Volume 204, Issue 11, pp: 1340–1343
Cystic Fibrosis–related Diabetes Is Associated with Worse Lung Function Trajectory despite Ivacaftor Use
Charles D. Bengtson *‡, Jianghua He *, Michael D. Kim , and Matthias A. Salathe
doi : 10.1164/rccm.202104-1060le
Volume 204, Issue 11, pp: 1343–1345
Olfactory Nasal Nitric Oxide Link in COVID-19: A Marker of Neurogenesis or Risk Factor for Chronic Rhinosinusitis?
Amit Jain
doi : 10.1164/rccm.202107-1697le
Volume 204, Issue 11, pp: 1345–1347
Reply to Jain: Olfactory Nitric Oxide Link in COVID-19: A Marker of Neurogenesis or Risk Factor for Chronic Rhinosinusitis?
Anh Tuan Dinh-Xuan * and Thông Hua-Huy ; on behalf of all the authors
doi : 10.1164/rccm.202108-1827le
Volume 204, Issue 11, pp: 1347–1348
Lung Cancer Screening
Yaron B Gesthalter and Eric J Seeley
doi : 10.1164/rccm.20411p19
Volume 204, Issue 11, pp: P19–P20
